Development of novel multinuclear magnetic resonance techniques in healthy volunteers and healthy patients
Healthy volunteers and healthy patients with known specific genotypes
Current interventions as of 13/08/2025: This is a single-centre, non-randomised, prospective, physiological imaging study including the following imaging techniques: • hyperpolarised 13C-MRSI • DMI • dynamic 2H-MRS and MRSI Imaging the following parts of the body: • brain • chest • abdomen/pelvis • breast • extremities Each participant may have up to five optional repeat scans within six months of their first scan. Imaging agent(s): 13C-pyruvate: a single IV injection of up to 40 mL at 0.4 mL/kg of [1-13C]-pyruvate. The maximum injection rate will be 5 mL/s. 2H-glucose: oral dose of [6,6’ 2H2] glucose dissolved in 200 to 300 mL of potable water giving a dose of 0.75 g/kg body weight, with a maximum of 60 g. Or A single IV injection of [6,6’ 2H2]-glucose 10-25% (w/v) giving a dose of up to 0.5 g/kg body weight, with maximum 35 g. The maximum injection rate will be 5 mL/s. Up to 6 administrations per study duration _____ Previous interventions: This is a non-randomised, physiological imaging study split into three imaging techniques across the body including: brain, chest, abdomen/pelvis, breast or extremities. MR imaging: 1. Following injection of 13C-pyruvate, using dynamic 13C MRI and MRSI in up to 40 healthy volunteers/healthy patients 2. Using Sodium MRI and MRSI in up to 40 healthy volunteers/healthy patients 3. Following oral consumption of a deuterated glucose drink or deuterated water, using dynamic deuterium metabolic MRI and MRSI imaging (DMI) in up to 40 healthy volunteers/healthy patients Healthy volunteers/healthy patients will be allocated to one of these imaging techniques by the Chief Investigator or delegate. This will be based on the availability of kits for the Hyperpolarised MRI study, the availability of the deuterated drink for the DMI study and/or the availability of the research MRI scanner. If healthy volunteers/healthy patients are willing, they may be recruited to all three arms to enable direct comparison. Each participant w
Inclusion criteria for healthy volunteers: 1. Over 18 years old 2. Able to and provide written informed consent to participate 3. If female, postmenopausal or if women of childbearing potential (WOCBP) using a suitable form of contraception 4. Capable of undergoing a minimum of one study visit Inclusion criteria for healthy patients at risk for hereditary metabolic disease: 1. Over 18 years old 2. Able to and provide written informed consent to participate 3. If female, postmenopausal or if of childbearing potential (WOCBP) using a suitable form of contraception 4. Capable of undergoing a minimum of one study visit 5. Carrying a pathogenic variant in the genes for succinate dehydrogenase and undergoing asymptomatic surveillance but without tumour manifestation
The presence of any of the following will preclude participation as determined by the delegated investigator: 1. Contraindication or inability to tolerate MRI 2. Pregnant or actively breastfeeding woman 3. If using an intrauterine contraceptive device (IUCD) as a method of contraception the device should be MRI-safe at 3 T (researcher to confirm) 4. Clinically significant cardiac, pulmonary or neurological diseases as determined by the investigators 5. Laboratory abnormalities that may impact the study results although no screening will be required for entry into the study. 6. Any other significant medical or psychiatric history rendering the subject ineligible as deemed by the investigators